Table 2. Meta-analyses and subgroup analyses for mortality.

Patients receiving immunotherapy vs. control patients	N of studies	Pooled OR (95%CI) a	I 2 (%) b	P	P for interaction
Overall	14	0.92 (0.68, 1.25)	4%	0.61
Study type
Prospective	3	0.67 (0.43, 1.04)	0%	0.07	0.054
Retrospective	11	1.19 (0.81, 1.73)	0%	0.38
Number of patients
<100	6	0.64 (0.28, 1.49)	0%	0.30	0.39
>100	8	0.97 (0.63, 1.49)	34%	0.90
Cancer type
Hematological malignancies	3	0.72 (0.27, 1.91)	0%	0.51	0.48
Solid tumor	3	1.10 (0.69, 1.76)	36%	0.68
Non-specific cancer	8	0.72 (0.39, 1.33)	8%	0.29
Immunotherapy interval before the COVID-19 diagnosis (days)
>20	8	0.98 (0.56, 1.69)	25%	0.94	0.44
<20	2	1.23 (0.54, 2.76)	0%	0.62
Number of patients receiving active immunotherapy
<10	7	0.75 (0.27, 2.08)	22%	0.58	0.66
>10	7	0.95 (0.70, 1.28)	0%	0.73

^aCalculated by using the random-effect model.

^bI ² means the inconsistency across studies.